Current Issue - Article Summary

Back to table of contents 3/15

Analgesia in mice with experimental meningitis reduces pain without altering immune parameters

Download article Download article (876 KB)
Sarah Mundt1, Marcus Groettrup1,2 and Michael Basler1,2
1 Division of Immunology, Department of Biology, University of Konstanz, Konstanz, Germany;
2 Biotechnology Institute Thurgau (BITg) at the University of Konstanz, Kreuzlingen, Switzerland


Intracranial lymphocytic choriomeningitis virus (LCMV) infection is a widely used animal model to study virus-induced cytotoxic T cell (CTL) mediated meningitis and immunopathology. This model causes severe pain and distress in mice, especially at later stages of the disease. Therefore, new treatment regimens to improve animal welfare have to be developed. In this study, we subcutaneously implanted ALZETĀ® osmotic pumps continuously releasing buprenorphine to reduce pain in mice with LCMV-induced meningitis. Mice treated with buprenorphine demonstrated strongly reduced symptoms of pain. The LCMV-specific cytotoxic T cell response and the immune cell infiltration into the central nervous system (CNS) were unchanged in analgesia treated mice, indicating that the LCMV-induced immune response was not altered in these mice. Taken together, we demonstrate that in this animal model for meningitis continuous buprenorphine treatment improves animal welfare without affecting the immune response. 

Keywords: 3R, refinement, meningitis, LCMV, pain

ALTEX 32(3), 183-189


Nach oben